Ian Shott has been appointed president of AMRI Europe, reporting to Thomas D’Ambra, Ph.D., chairman, president and chief executive officer. Mr. Shott will have responsibility for AMRI’s business operations in Europe, including the company’s site in Wales, UK, and will work closely with the business development team.
 
Mr. Shott has more than 20 years of experience working with global pharmaceutical, biotechnology, and chemical companies. He was the founder and chief executive officer of Excelsyn, now AMRI UK, which was acquired in February 2010. Mr. Shott serves as managing director of Shott Consulting Ltd., where he provides consulting services to the healthcare and chemical industries, as well as industry boards. Mr. Shott’s earlier career included executive board positions at RhodiaChirex in France, Chirex in the U.S., Lonza in Switzerland, and Astra Zeneca in the UK.
 
“Mr. Shott brings an intimate knowledge of the AMRI UK site including its capabilities and leadership team, which will enable him to quickly embark on customer and business growth initiatives,” Dr. D’Ambra said. “His extensive experience and skills strengthen our position in the European marketplace. His unique insights are a good fit with our AMRI SMARTSOURCING brand and I look forward to his contributions in building strategic relationships with a broader customer base, which benefits all of our locations.”